Previous Close | $72.77 |
Intrinsic Value | $57.85 |
Upside potential | -21% |
Data is not available at this time.
Corcept Therapeutics Incorporated operates in the biopharmaceutical sector, specializing in the development and commercialization of drugs targeting cortisol dysregulation. The company’s flagship product, Korlym (mifepristone), is FDA-approved for treating hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome. Corcept’s revenue model hinges on direct sales in the U.S., supported by a focused commercialization strategy targeting endocrinologists and specialized treatment centers. The company maintains a strong market position in the niche but growing field of cortisol modulation therapies, with limited competition due to the complexity of the condition and regulatory barriers. Corcept’s pipeline includes next-generation cortisol modulators, positioning it for potential expansion into broader endocrine and metabolic disorders. Its research-driven approach and targeted commercialization underscore its differentiation in a specialized therapeutic area.
Corcept reported $675.0 million in revenue for FY 2024, reflecting steady demand for Korlym. Net income stood at $139.7 million, with diluted EPS of $1.23, indicating robust profitability. Operating cash flow of $198.1 million highlights efficient cash generation, while modest capital expenditures of $2.2 million suggest a capital-light model focused on commercialization rather than heavy infrastructure investment.
The company demonstrates strong earnings power, with net income margins exceeding 20%. Capital efficiency is evident in its high return on assets, driven by focused R&D spending and scalable commercialization. Corcept’s ability to generate significant cash flow relative to its asset base underscores its disciplined approach to resource allocation.
Corcept maintains a solid balance sheet, with $127.7 million in cash and equivalents and minimal total debt of $6.9 million. The negligible leverage and strong liquidity position provide flexibility for strategic investments or pipeline expansion. Shareholders’ equity remains healthy, supported by retained earnings from consistent profitability.
Revenue growth has been steady, driven by Korlym’s adoption and pricing power. The company does not pay dividends, opting instead to reinvest cash flows into R&D and potential acquisitions. Future growth may hinge on pipeline advancements, including next-generation cortisol modulators and label expansions.
The market values Corcept at a premium, reflecting its niche leadership and high margins. Investors likely anticipate pipeline success and sustained revenue growth, though risks include reliance on a single product and regulatory uncertainties. The current EPS multiple suggests optimism about future earnings potential.
Corcept’s deep expertise in cortisol modulation and first-mover advantage with Korlym provide durable competitive edges. The outlook remains positive, with potential upside from pipeline progress. However, diversification beyond Korlym and navigating regulatory pathways will be critical for long-term success.
Company filings (10-K), investor presentations
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |